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The CD40 ligand (CD40L) and CD40 are two molecules belonging to the TNF/TNF receptor super-
family, and their role in adaptive immune system has widely been explored. However, the wide
range of expression of these molecules on hematopoietic as well as nonhematopoietic cells has
revealed multiple functions of the CD40/CD40L interactions on different cell types and processes
such as granulopoiesis. CD40 triggering on stromal cells has been documented to enhance the
expression of granulopoiesis growth factors such as granulocyte-colony-stimulating factor (G-
CSF) and granulocyte/monocyte-colony-stimulating factor (GM-CSF), and upon disruption of the
CD40/CD40L-signaling pathway, as in the case of X-linked hyperimmunoglobulin M (IgM) syn-
drome (XHIGM), it can lead to neutropenia. In chronic idiopathic neutropenia (CIN) of adults,
however, under the inﬂuence of an inﬂammatory microenvironment, CD40L plays a role in granu-
locytic progenitor cell depletion, providing thus a pathogenetic cause of CIN.
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1. INTRODUCTION
CD40 ligand (CD40L) is a type II transmembrane protein belonging to the tumor necrosis factor (TNF)
family, andits geneis locatedontheqarm ofchromosomeX[1]. Followingactivation,it canbeupregulated
predominantly on CD4+ T-cells and platelets, but also on CD8+ T-cells, natural killer (NK) cells, B-
cells, dentritic cells (DCs), monocytes/macrophages, basophils, eosinophils, and endothelial cells [1, 2].
Its receptor, CD40, is a type I transmembrane protein, belonging to the TNF receptor superfamily and is
encoded by the gene located on the q arm of chromosome 20 [3]. CD40 is constitutively expressed on
normal and leukemic B cells, as well as on monocytes, macrophages, endothelial cells, epithelial cells,
smooth muscle cells (SMCs), DCs, ﬁbroblasts, and adipocytes [1, 4].
The cytoplasmic domain of CD40 lacks intrinsic signaling activity, and upon ligation, it recruits
adaptor proteins, namely, the tumour receptor-associated factors (TRAFs) to initiate different downstream
signaling pathways resulting in a wide spectrum of cell-type speciﬁc actions [5]. The role of CD40-CD40L
interactions on adaptive immunity has been extensively studied [6, 7]. Upon ligation, CD40 stimulates
B-cell proliferation and differentiation into plasma cells, germinal center formation, immunoglobulin
switching, and somatic hypermutations [8, 9], while it is also involved in the development of thymocytes
and differentiation of na¨ ıve CD4+ T cells [10–13]. Furthermore, CD40-40L interactions play an important
role in innate immunity [6, 14], apoptosis [15, 16], inﬂammtion, and a number of autoimmune diseases
[17–20].
Therole ofCD40-CD40Ldyad,however,hasnot beenelucidatedin normalgranulopoiesisaswell as
in neutropenia states. In this paper we will highlight the role of CD40L in the development of granulocytic
cells.
2. GRANULOPOIESIS
Granulopoiesisisacomplexprocessinwhichalargenumberofgranulocytesisformedfromasmallnumber
of hemopoietic stem cells (HSCs) that can replicate and differentiate into multilineage-(common mye-
loid progenitors; CMPs), double-lineage-(granulocyte/macrophage progenitors; GMPs), and unilineage-
committed progenitor cells which further multiply and differentiate into functional mature neutrophils
[21, 22]. In early granulopoiesis, granulocyte/monocyte-colony-forming units (CFU-GM), which express
the CD34+ surfaceantigen, giverise to granulocyte-colony-formingunits (CFU-G), while in the later stages
of neutrophil maturation, myeloblasts, being the ﬁrst morphologically distinguishable cells of granulocytic
lineage expressing both CD34 and CD33 antigens, can divide and differentiate into promyelocytes
(CD34−/CD33+), myelocytes (CD34−/CD33+), which further differentiate into metamyelocytes, band
cells (CD33−/CD15+), and ﬁnally neutrophils [23–26].
The whole process is strictly controlled by transcription factors, such as CCAAT/enhancer-binding
protein alpha (c/EBPα), PU.1, c-Myb, lymphoid enhancer-binding factor-1 (LEF-1), c/EBPε [27–30],
and growth factors and cytokines like stem-cell factor (SCF), FMS-like tyrosine kinase 3 ligand (Flt3-
L), interleukin(IL)-3, granulocyte/monocyte-colony-stimulatingfactor (GM-CSF), and granulocyte-colony
stimulating factor (G-CSF) [31–36]. In vivo, the growth factors that promote granulopoiesis are produced
mainly in the bone marrow (BM) stromal microenvironment as indicated from in vitro experiments with
long-term BM cultures (LTBMCs), where a stromal layer of adherent cells consisting mostly of ﬁbroblasts,
macrophages, endothelial cells, and adipocytes can produce constitutively or after stimulation the above
mentioned growth factors [37–40].
Among the major regulators of granulopoiesis are the GM-CSF and G-CSF that can act through
their receptors on a range of hematopoietic as well as nonhematopoietic cells [41–43]. G-CSF is pro-
ducedby monocytesandmacrophages,ﬁbroblasts, andendothelial cells following stimulation with lipopol-
ysaccharide (LPS), IL-1, IL-3, GM-CSF, TNFα, and interferon (IFN)-γ [44–48]. It controls the survival,
proliferation, and differentiation of cells along the granulocytic pathway and is necessary for their terminal
differentiation to mature neutrophils [49–51]. GM-CSF is produced by macrophages, T lymphocytes,
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ﬁbroblasts,endothelialcells,andstromalcells, whichin mostcasesrequire stimulation with cytokines,anti-
gens, or inﬂammatory agents [39, 52–55].
GM-CSF promotes the proliferation and maturation of neutrophils, and macrophages from BM
progenitors can interact with other factors, which may elevate or decrease cell growth in the presence of
different amounts of the cytokine [35, 36, 56, 57].
3. THE GRANULOPOIESIS-PROMOTING EFFECT OF CD40L
As mentioned above, BM stromal cells express constitutively or under stimulation CD40 on their surface,
and upon engagement with CD40L and/or other stimuli, they can upregulate the expression of GM-CSF
and G-CSF, two of the key regulators of granulopoiesis. It has been demonstrated that CD40 triggering
on endothelial cells as well as on SMCs enhances the production of GM-CSF [58, 59]. Endothelial cells
and macrophages have also been reported to upregulate IL-1β and IFNγ expression upon CD40 ligation
[6, 60–62], which, in turn, act synergistically with CD40L on ﬁbroblasts to induce GM-CSF expression
[63]. Consistent with these hypothesiswas the observedupregulation of GM-CSF on thymic epithelial cells
following activation with IL1, IFNγ, andCD40L [64]. Furthermore, in a recent work from our group,it was
demonstrated that CD40 engagement on BM stromal cells from healthy donors resulted in increased levels
of both G- and GM-CSF in the supernatants of LTBMCs [65]. In addition, when BM mononuclear cells
(BMMCs) obtained from healthy subjects were cocultured with the adherent-cell layer of normal LTBMCs
in the presence of CD40L and assessedfor clonogenic progenitor cells, the number of granulocytic-colony-
forming units (CFU-G) was increased comparing with the untreated cultures [65]. Our data corroborate the
granulopoiesis-inducing effect of CD40/CD40L through G- and GM-CSF induction BM stroma.
Flt3-L, which is another hematopoiesis/granulopoiesis-promoting factor that acts on primitive and
myeloid-committed hematopoietic cells [66, 67], was shown to be upregulated upon CD40 stimulation on
ﬁbroblasts, endothelial cells, and stromal cells from LTBMCs. Furthermore, in CD40L-induced cocultures
of endothelial cells (ECs) with CD34+ cells, the production of Flt3-L increased the number of clonogenic
cells [68]. In the same work, CD40 ligation on all stromal cell types resulted in thrombopoietin (TPO)
expression, a regulator of early hematopoiesis [69].
4. CD40L AND NEUTROPENIA
The CD40-CD40L couple is implicated in different types of neutropenia with distinct pathogenetic cause.
The X-linked hyperimmunoglobulin M (IgM) syndrome (XHIGM) is a rare immunodeﬁciency disease
characterized by normal or elevated serum IgM, reduced levels of IgG, IgA, and IgE, and defective T-cell
function. The most common clinical signs are infections, arthritis, and mucosal ulcers. In the majority of
patients, the syndrome is due to mutations of the gene encoding for CD40L on chromosome X, and almost
70% of these patients have neutropenia, 45% of whom having chronic neutropenia, without the presence of
antineutrophilantibodies[70–72](Table 1).TheetiologyofneutropeniainXHIGM isnotwellknown,butit
hasbeenhypothesizedthatabnormalCD40Linteractionswith stromalcellsresultingin ineffectivesynthesis
of granulocyte-inducing growth-factors may have a role. In favor of this hypothesis is the ﬁnding that treat-
ment ofpatientswith recombinantG-CSF resultsin increasedornormallevelsofneutrophil counts[73,74].
Chronic idiopathic neutropenia (CIN) of adults is an acquired form of neutropenia representing the
mild form of the spectrum of BM failure syndromes that are characterized by T-cell and cytokine-mediated
suppression of hematopoiesis. The pathogenetic cause of neutropenia is in large due to impaired BM
granulopoiesis, and it has been documented defective CFU-G growth potential of BMMCs as well as a
lower frequency of CD34+/CD33+ cells which was correlated with Fas overexpression and accelerated
Fas-mediatedapoptosis within this strictly deﬁned cell compartment [76]. In addition, an inﬂammatory BM
microenvironment with elevated levels of TNFα,I L - 1 β,T G F β1, IL-6 as well as IFN-γ and Fas-ligand-
producing activated T-lymphocytes has been documented previously in CIN patients [75, 77, 78]( Table 1).
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TABLE 1: Pathogenetic and pathophysiologic features of X-linked Hyper IgM Syndrome and Chronic Idio-
pathic Neutropenia.
X-linked hyper-IgM syndrome Chronic idiopathic neutropenia
Clinical features
Infections, arthritis,mucosal ulcers, and
neutropenia [70–72]
Neutropenia, and
osteopenia/osteoporosis, usually
uncomplicated course [75]
Immunologic Features/cytokines
Elevated IgM, reduced IgG, IgA, and
IgE levels [70–72]
Elevated TNFα,I F N γ,T G F β,
IL-1β, IL-6, and FasL [75–77]
Pathophysiologicfeatures
Mutations in the CD40L gene,
abnormal T-cell mediated signals,
failure of B-cell differentiation, and
defective regulation of immunoglobulin
isotype switching [70–72]
Impaired BM granulopoiesis and
T-cell and cytokine-mediated
suppression of hematopoiesis
[75–78]
Abbreviations: IgM, immunoglobulin-M; IgG, immunoglobulin-G; IgA, immunoglobulin-A; IgE, immunoglobulin-E; TNFα, tumour necrosis
factor-α;T G F β, transforming growth factor-β;I L - 1 β, inteleuκin-1β; IL-6, interleukin-6; BM, bone marrow.
In a recent study of our group, it was demonstrated that CD40 was minimally expressed on normal
BM granulocytic progenitorand precursorcells, namely, the CD34+,C D 3 4 −/CD33+, and CD34−/CD33−/
CD15+ cell subpopulations; however, CD40 was upregulated upon TNFα stimulus in in vitro cultures,
and upon ligation with CD40L, it resulted in the increased amount of apoptotic cells in the CD40+ cell
compartment compared to untreated cells or TNFα-treated cells [65]. Furthermore, CD40 triggering re-
sulted in Fas expression on these cell populations, which upon stimulation with rhFasL in the presence of
bothTNFα andCD40L,it resultedin afurther increaseofapoptoticcellsin anadditiveway.However,when
Fas receptor was blocked, CD40L could still initiate apoptosis on granulocytic subpopulations, leading to
the assumption that CD40-CD40L interactions can act either directly or indirectly via the Fas-FasL system
to induceapoptoticeffectsongranulocyticprogenitorandprecursorcells[65]. Byevaluatingtheclonogenic
potential of normal and CIN BMMCs under the inﬂuence of rhCD40L, it was shown that the number of
CFU-G of both groups was decreased although not in a statistically signiﬁcant way in healthy controls. The
prominent decrease of CFU-Gs in CIN patients could be due to increased endogenousTNFα levels in these
patients [75] with a subsequentoverexpressionof CD40 on progenitor and precursor cell surface, rendering
those cells more susceptible to the apoptotic effect of CD40 as shown above [65].
Finally, when clonogenic assays were performed with the nonadherent cells of LTBMCs following
coculture with the adherent cells of stromal layer of LTBMCs in the presence of CD40L alone, the number
of CFU-Gs was increased in the case of normal supernatant cells incubated on normal stromal layer as
opposed to the decrease in the CFU-Gs in the case of CIN supernatant cells incubated on CIN stromal layer
[65]. However, when the nonadherent cell of LTBMCs of CIN patients were incubated with normal stromal
layer in the presenceof CD40L alone, the decreasein CFU-Gs previously seen was less (unpublished data).
These observations lead to the assumption that CD40L which can be expressed by activated T-lymphocytes
present in the BM of CIN patients is a potent effector of granulocytic progenitor cell depletion, resulting in
neutropenia, even counterbalancing the beneﬁcial effect of elevated G-CSF found in those patients [75].
5. CONCLUSION
The fact that CD40L induces the expression of granulopoiesis-promoting factors such as G-CSF, GM-CSF,
and Flt3-L from normal stromal cells leads to the hypothesis that the cytokine could act as a granulopoiesis
stimulating molecule under steady state conditions. However, under the inﬂuence of an inﬂammatory mi-
croenvironment as in the case of CIN, where there are elevated levels of proinﬂammatory cytokines like
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FIGURE 1: Schematic diagram of the CD40/CD40L interactions in the bone marrow. Under steady
state conditions, CD40 is minimally expressed on the BM granulocytic progenitor cells, but it is consti-
tutively expressed on BM stromal cells, and upon ligation with CD40 ligand (CD40L), it induces the pro-
duction of FMS-like tyrosine kinase 3 ligand (Flt3-L), granulocyte-colony-stimulating factor (G-CSF), and
granulocyte/monocyte-colony-stimulating factor (GM-CSF). Under inﬂammatory conditions, involving in-
creased tumour necrosis factor-α (TNFα), Fas ligand (FasL), and CD40L production, as found in the BM
microenvironment of chronic idiopathic neutropenia (CIN) patients, CD40 expression is upregulated in all
stages of the granulocytic differentiation, and upon activation with CD40L, it induces the apoptotic cell death
both directly and indirectly through Fas upmodulation, counterbalancing the beneﬁcial effect of G-CSF and
GM-CSF produced by BM stromal cells.
TNFα and IFN-γ, which can induce further the expression of CD40 on granulocytic progenitor and precur-
sor cells, CD40L can act as a granulopoiesis-inhibitory molecule due to increased apoptosis of these cell
populations. Accordingly, the CD40-CD40L interactions display a dual effect on granulopoiesis (Figure 1).
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